Journal of Contemporary Brachytherapy, published by TERMEDIA PUBLISHING HOUSE LTD, is a distinguished open-access journal dedicated to advancing the field of brachytherapy within the oncology and radiology domains. Since its inception in 2009, the journal has provided a platform for researchers, clinicians, and students to share innovative findings, cutting-edge techniques, and clinical experiences, contributing significantly to evidence-based practices in cancer treatment. With an ISSN of 1689-832X and E-ISSN 2081-2841, the journal has established its presence globally, and it is indexed in Scopus, achieving a commendable standing among its peers—with rankings of #196 in Radiology, Nuclear Medicine, and Imaging and #260 in Oncology for 2023. Notably, it holds a Q3 quartile classification, reflecting its emerging influence in these critical fields. The journal is committed to open science, ensuring that research is accessible to a wide audience, which is particularly vital for the ongoing development of methodologies and the implementation of best practices in brachytherapy. Exploring topics from the technical aspects of brachytherapy procedures to patient management strategies, the Journal of Contemporary Brachytherapy is an essential resource for those looking to stay at the forefront of oncological advancements.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

GYNECOLOGIC AND OBSTETRIC INVESTIGATION, published by KARGER, is an influential journal dedicated to advancing the fields of obstetrics and gynecology. With an ISSN of 0378-7346 and E-ISSN 1423-002X, this esteemed publication has been disseminating pivotal research since 1895 and continues to serve as an authoritative source through its convergence until 2024. Renowned for its rigorous adherence to academic standards, it stands in the Q2 category for both Obstetrics and Gynecology and Reproductive Medicine as of 2023, reflecting its quality and impact within the scientific community. With Scopus rankings highlighting its commendable positions—Rank #66 in Obstetrics and Gynecology and Rank #31 in Reproductive Medicine—it is an essential resource for researchers, professionals, and students alike, fostering a deeper understanding of women’s health issues and innovative care practices. Despite not being an open-access journal, its contributions significantly influence current and future directions in clinical and translational research.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Gland Surgery, an esteemed journal published by AME PUBLISHING COMPANY, is at the forefront of surgical research, particularly focusing on advancements in gland-related surgeries and their clinical implications. With an ISSN of 2227-684X and an E-ISSN of 2227-8575, this open-access journal provides a platform for disseminating high-quality research and insights into the intricate aspects of surgical practices, ranking in the Q2 category in Surgery as of 2023. As evidenced by its Scopus ranking at #153 out of 551 in the Medicine_Surgery field, Gland Surgery delivers valuable contributions to the global medical community, promoting the exchange of knowledge and innovative techniques. Operating from Hong Kong, China, and converging its excellence from 2016 to 2024, the journal is a critical resource for researchers, clinicians, and students keen on exploring the latest developments in the field. By fostering an open dialogue among professionals, Gland Surgery is accessible to a diverse audience seeking to enhance their understanding and practice in gland surgery.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.